Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

175

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2029

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

WVE-N531

WVE-N531 is an antisense oligonucleotide (ASO)

Trial Locations (3)

Istiklal Hospital/ Clinical Research Unit, Amman

The Specialty Hospital (TSH)/ Advanced Clinical Center, Amman

Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust, Headington

All Listed Sponsors

lead

Wave Life Sciences Ltd.

INDUSTRY

NCT07209332 - Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter